

Lenvima (levatinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

| MEMBER INFORMATION | | |
|------------------------------|----------------|-----------|
| LAST NAME: | FIRST NAME: | |
| PHONE NUMBER: | DATE OF BIRTH: | |
| STREET ADDRESS: | | |
| CITY: | STATE: | ZIP CODE: |
| PATIENT INSURANCE ID NUMBER: | | |

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

| PRESCRIBER INFORMATION | | | |
|---|------------------------|-----------|--|
| LAST NAME: | FIRST NAME: | | |
| PRESCRIBER SPECIALTY: | EMAIL ADDRESS: | | |
| NPI NUMBER: | DEA NUMBER: | | |
| PHONE NUMBER: | FAX NUMBER: | | |
| STREET ADDRESS: | | | |
| CITY: | STATE: | ZIP CODE: | |
| REQUESTER (if different than prescriber): | OFFICE CONTACT PERSON: | | |

| MEDICATION OR MEDICAL DISPENSING INFORMATION | | | |
|---|------------|----------------------------|-----------|
| MEDICATION NAME: | | | |
| DOSE/STRENGTH: | FREQUENCY: | LENGTH OF THERAPY/REFILLS: | QUANTITY: |
| <input type="checkbox"/> NEW THERAPY <input type="checkbox"/> RENEWAL IF RENEWAL: DATE THERAPY INITIATED: | | | |
| DURATION OF THERAPY (SPECIFIC DATES): | | | |

Continued on next page



Lenvima (levatinib)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

| 1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? | | |
|---|--|---|
| <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO | | |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): | DURATION OF THERAPY (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: |
| 2. LIST DIAGNOSES: | | ICD-10: |
| <input type="checkbox"/> Thyroid cancer <input type="checkbox"/> Unresectable hepatocellular carcinoma <input type="checkbox"/> Advanced renal cell carcinoma <input type="checkbox"/> Advanced endometrial carcinoma <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): | | |
| 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION. | | |
| Is patient going to be using drug in a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No For <u>thyroid cancer</u>, answer the following: Is patient's thyroid cancer locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart documentation.</i> Has patient had prior treatment with 2 or more other tyrosine kinase inhibitors? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart documentation.</i> For <u>unresectable hepatocellular carcinoma</u>, answer the following: Will Lenvima (lenvatinib) be used as first-line treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No For <u>advanced renal cell carcinoma</u>, answer the following: Does the patient's renal cancer have a clear-cell component? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart documentation or histology report.</i> Has patient previously received any systemic anticancer therapy for advanced disease? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart documentation.</i> Will Lenvima be used in combination with Keytruda® (pembrolizumab)? <input type="checkbox"/> Yes <input type="checkbox"/> No For <u>advanced endometrial carcinoma</u>, answer the following: Has the patient's disease progressed following prior systemic therapy with a platinum based chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart documentation.</i> Has the patient had more than TWO prior lines of systemic therapy with a platinum based chemotherapy, either one given as neoadjuvant and one given as adjuvant? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart documentation.</i> Does the patient have an ECOG score of 0 or 1? <input type="checkbox"/> Yes <input type="checkbox"/> No | | |



Lenvima (levatinib)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Will Lenvima(levatinib) be used in conjunction with pembrolizumab (Keytruda®)? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201

P.O. Box 64811

St. Paul, MN 55164-0811

Phone: 877-228-7909